Weaponized Antibodies Use New Tricks To Fight Cancer
After decades of frustration, efforts to develop antibodies that can ferry drugs into cancer cells—and minimize damage to healthy tissue—are gathering steam. The next generation of these ‘weaponized antibody’ therapies, called antibody–drug conjugates (ADCs), is working its way through clinical trials. Researchers will gather to discuss this renaissance on 30 November at the Symposium on Molecular Targets and Cancer Therapeutics in Munich, Germany. The improvements come after the first wave of experimental ADCs failed to deliver on its promise....